FindMyKOL
Clinical trialNCT05250947TerminatedPhase 1Interventional

Study Evaluating the Safety and Feasibility of Platelet-rich Plasma to Treat Facetogenic Low Back Pain

NCT05250947 is a phase 1 interventional trial sponsored by Matthew Pingree. As of 18 Nov 2026, it was terminated. It studies Platelet Rich Plasma in Lumbar Spondylosis. The registry lists an enrollment of 4 participants at 1 site in 1 country. The registry lists a start date of 5 Jan 2023 and a primary completion date of 20 May 2024.

SponsorMatthew PingreeEnrollment4Lumbar Spondylosis
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT05250947
FieldValue
Registry IDNCT05250947
StatusTerminated
PhasePhase 1
Study typeInterventional trial
Lead sponsorMatthew Pingree
Enrollment4
Registered sites1
Countries1
ConditionsLumbar Spondylosis
DrugsPlatelet Rich Plasma
Start5 Jan 2023
Primary completion20 May 2024
Study completion20 May 2024
Last update posted17 Jul 2024

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study is being done to assess the safety of using the Angel Concentrated Platelet Rich Plasma System to process Platelet Rich Plasma (PRP) to treat arthritis of the low back (lumbar spondylosis).

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Minnesota, United States1 site
  • Mayo Clinic in Rochester

    Rochester

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesota: 1 siteMN1WisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Platelet Rich Plasma
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT05250947

Each answer restates registry values shown on this page.

What is NCT05250947?

NCT05250947 is a phase 1 interventional trial sponsored by Matthew Pingree. It studies Platelet Rich Plasma in Lumbar Spondylosis.

Who leads NCT05250947?

The registry names Matthew Pingree, MD (principal investigator, Mayo Clinic) as the overall official.

Where does NCT05250947 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT05250947 study?

The registered drug and biological interventions are Platelet Rich Plasma.

When did NCT05250947 end?

The registry lists a primary completion date of 20 May 2024 and a study completion date of 20 May 2024. The sponsor last updated the record on 17 Jul 2024.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 18 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.